BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Aflibercept
1
Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture
4/9/2021 8:11:25 AM | Browse: 581 | Download: 852
2
Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
2/22/2019 4:33:37 AM | Browse: 936 | Download: 931
3
Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
2/22/2019 4:33:37 AM | Browse: 839 | Download: 797
4
FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer
9/14/2018 11:38:00 AM | Browse: 941 | Download: 1240
5
Role of targeted therapy in metastatic colorectal cancer
9/12/2016 10:43:00 AM | Browse: 964 | Download: 1322
6
Treatment of diabetic retinopathy: Recent advances and unresolved challenges
8/23/2016 8:55:00 AM | Browse: 984 | Download: 1413
7
New active drugs for the treatment of advanced colorectal cancer
12/24/2015 8:55:00 AM | Browse: 871 | Download: 1365
8
Curing diabetic retinopathy: Is a strategy emerging?
11/13/2015 3:33:00 PM | Browse: 1091 | Download: 1518
9
Anti-angiogenic therapies for metastatic colorectal cancer: Current and future perspectives
9/11/2014 8:40:00 PM | Browse: 979 | Download: 1323
10
Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema
9/1/2014 2:50:00 PM | Browse: 956 | Download: 955
11
Advances and new perspectives in the treatment of metastatic colon cancer
8/26/2014 4:37:00 PM | Browse: 1072 | Download: 1145
Write to the Help Desk
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345